SiCureMi is a healthtech startup based in India, that builds a prescription-understanding product and a non-invasive cardiovascular risk screening tool for patients and doctors.

This Startup Deep Dive explains what SiCureMi does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

SiCureMi in Brief

• What it is: SiCureMi is an Indian Healthtech, preventive screening company based in New Delhi / Noida area (reports differ).
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The KYP product helps patients understand their prescriptions.
• A non-invasive screening tool helps doctors assess cardiovascular disease risk; one report ties it to a retina-based approach using OCTA and AI.
• The company uses machine learning, AI-based analytics and IoT sensors for continuous monitoring and early detection of lifestyle diseases.
• Funding: About $1.18M across two seed rounds (reported), listed mainly from BIRAC.

SiCureMi Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is SiCureMi?

SiCureMi operates in the Healthtech, preventive screening space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to SiCureMi.

• The KYP product helps patients understand their prescriptions.
• A non-invasive screening tool helps doctors assess cardiovascular disease risk; one report ties it to a retina-based approach using OCTA and AI.
• The company uses machine learning, AI-based analytics and IoT sensors for continuous monitoring and early detection of lifestyle diseases.
• A self-care app and SaaS platform combine health parameters to generate risk scores for lifestyle diseases.
• It pulls activity data such as steps, sleep and heart rate along with medication history and lab reports so physicians can tailor care (as described by a database).

The Origin Story of SiCureMi

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Tarun Gupta, Prakash Thakur, Apoorva Mathur, Sudeep Reddy.
• The legal entity, SiCureMi Healthcare Technologies Private Limited, was incorporated on 24 April 2018 per registry listings.
• Founder Tarun Gupta reportedly started the company in late 2018 to close the gap in patients' understanding of prescriptions.
• Founder lists differ by source: Tarun Gupta and Prakash Thakur in some, Apoorva Mathur, Prakash Thakur and Sudeep Reddy in others (Crunchbase lists Mathur as clinical head and Reddy as CTO).

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Healthtech, preventive screening sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• April 2018: legal entity incorporated.
• 2018-2019: supported by incubators including C-CAMP in Bengaluru.
• September 2021: two seed-stage rounds reported at about $1.18M in total, with BIRAC the main named investor.
• FY25: reported revenue of about Rs 17.1 lakh (database figure).

SiCureMi Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Seed, September 2021, about $750K, BIRAC plus other investors (reported).
• Seed, September 2021, about $425K, BIRAC plus other investors (reported); another database dates an earlier seed to January 2020.
• Other investors named include Centre for Cellular and Molecular Platforms and COPIC (reported).

How Does SiCureMi Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• SaaS platform that generates risk scores for lifestyle diseases, sold to doctors and healthcare providers.
• Patient-facing prescription understanding product (KYP) and a doctor-facing cardiovascular screening tool; pricing is not public.

The Numbers: SiCureMi Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY25 revenue about Rs 17.1 lakh (reported by a database, from a very small base).
• Funding about $1.18M across two seed rounds.
• Cap table as of 31 March 2024: founders about 55.7%, investors about 44.3%; Tarun Gupta largest holder at 40.8% (reported).

Market Opportunity for SiCureMi

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• The company targets patients and doctors in lifestyle and cardiovascular disease detection.
• Cardiovascular and lifestyle diseases are a major burden in India, making early risk screening a large addressable need (general framing, not from a cited figure).

Technology and Product at SiCureMi

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Machine learning, AI-based analytics and IoT sensors.
• One report says its cardiovascular risk approach differs from existing fundus scanning by using OCTA and AI.

Team and Culture at SiCureMi

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Tarun Gupta is founder and CEO in several profiles.
• Prakash Thakur and Apoorva Mathur are named as co-founders; Sudeep Reddy appears as CTO in one database.
• A startup database lists about 3 employees.

SiCureMi Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for SiCureMi

• The company is at seed stage with a very small reported team and tiny revenue.
• No funding or product news after 2021 was found.
• Sources disagree on founding year, founders and base city.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

SiCureMi Growth Outlook: What to Watch

• No recent announcements were found, so the near-term plan is unknown.
• Its direction as of 2021 was to scale screening and risk-scoring tools for doctors.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether SiCureMi can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where SiCureMi Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for SiCureMi

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for SiCureMi.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from SiCureMi

Studying a company in the Healthtech, preventive screening space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about SiCureMi.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate SiCureMi as a Startup

• Customer clarity: Can SiCureMi name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

SiCureMi is part of India’s growing Healthtech, preventive screening ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

SiCureMi FAQs: Frequently Asked Questions

What is SiCureMi?

SiCureMi is a healthtech startup based in India, that builds a prescription-understanding product and a non-invasive cardiovascular risk screening tool for patients and doctors. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded SiCureMi?

SiCureMi was founded by Tarun Gupta, Prakash Thakur, Apoorva Mathur, Sudeep Reddy, and the company reports a founding year of reports differ: 2017 and 2018 (entity incorporated April 2018).

How much funding has SiCureMi raised?

About $1.18M across two seed rounds (reported), listed mainly from BIRAC. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does SiCureMi make money?

SiCureMi earns revenue from its Healthtech, preventive screening products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of SiCureMi?

Reported rivals include PrediScan, Sunfox Technologies, Accord Innovations. See the competitor comparison above for how they differ.

What are the main risks for SiCureMi?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Kinara Capital — Kinara Capital: women-led MSME lender raised ~Rs 200 crore in 2022 | Vyom Space — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.